Northpond Ventures co-leads US$55 million Series A financing round for Triumvira Immunologics

27 August 2020

On August 27, 2020, Triumvira Immunologics Inc. successfully completed a US$55 million Series A financing round. The financing was co-led by Northpond Ventures, LLC and Leaps by Bayer, the impact investment unit of Bayer AG. Additional investors include Oceanpine Capital and Viva Biotech Holdings, and existing investors include Bloom Burton & Co. and the Centre for Commercialization of Cancer Immunotherapy (C3i).

Triumvira is a US-based, privately-held biopharmaceutical company with operations both in the US and Canada.  The company is developing a novel platform for engineering T-cells to attack cancers.

Northpond, headquartered in the US, is a leading global science, medical, and technology-driven venture firm dedicated to building and empowering breakthrough companies in life sciences and technology. Northpond has in excess of $1 billion of committed capital, with over 21 businesses represented in its portfolio.

Gowling WLG was Canadian counsel to Northpond on certain aspects of this financing with a team led by Derek Keay and including Garrett Hamel, Anita Nador and Lorne Segal.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.